488713-31-1

Basic information

• Product Name: 2-PYRIDINECARBONITRILE, 5-AMINO-3-CHLORO-
• Synonyms: 2-PYRIDINECARBONITRILE, 5-AMINO-3-CHLORO-;5-AMino-3-chloropyridine-2-carbonitrile;5-amino-3-chloropicolinonitrile;5-Amino-3-chloro-2-cyanopyridine;5-Amino-3-chloro-2-pyridinecarbonitrile
• CAS NO: 488713-31-1
• Molecular Formula: C6H4ClN3
• Molecular Weight: 153.572
• Mol File: 488713-31-1.mol

Chemical Properties

• Boiling Point: 400.477 °C at 760 mmHg
• Flash Point: 196.001 °C
• Appearance: /
• Density: 1.427 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-PYRIDINECARBONITRILE, 5-AMINO-3-CHLORO-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PYRIDINECARBONITRILE, 5-AMINO-3-CHLORO-(488713-31-1)
• EPA Substance Registry System: 2-PYRIDINECARBONITRILE, 5-AMINO-3-CHLORO-(488713-31-1)

Safety Data

• Hazardous Substances Data: 488713-31-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarbonitrile, 5-amino-3-chlorois used as an intermediate in the synthesis of a wide range of pharmaceuticals. Its unique structure allows for the development of drugs with diverse therapeutic applications, including anti-inflammatory, anti-cancer, and antimicrobial agents. The presence of the amino and chloro groups in its structure enables the formation of various functional groups, making it a valuable building block in drug synthesis.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Pyridinecarbonitrile, 5-amino-3-chlorois used as a precursor in the production of various agrochemicals, such as insecticides, herbicides, and fungicides. Its ability to form different functional groups makes it a versatile compound for the development of effective and targeted agrochemicals.
Used in Dyes and Pigments Production:
2-Pyridinecarbonitrile, 5-amino-3-chlorois also used in the production of dyes and pigments. Its unique chemical structure allows for the creation of a variety of colors and shades, making it a valuable component in the formulation of dyes and pigments for various applications, including textiles, plastics, and printing inks.

Upstream product

• 488713-30-0 3-chloro-5-nitropyridine-2-carbonitrile 
• 7439-89-6 iron 
• 945557-04-0 5-bromo-3-chloro-pyridine-2-carbonitrile 
• 1186637-78-4 tert-butyl 5-chloro-6-cyanopyridin-3-ylcarbamate 
• 488713-29-7 3-chloro-2-iodo-5-nitropyridine 
• 22353-40-8 2,3-dichloro-5-nitropyridine 

Relevant articles and documents

DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.

Bicyclic modulators of androgen receptor function

The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.

BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION

The invention provides compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.